PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 5, 2025Hematology0 citations

JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches

View Full Paper
NSNatasha SzuberATAyalew Tefferi

Key Points

  • Polycythemia vera exclusion is crucial for diagnosing erythrocytosis, differentiating between hereditary and acquired cases.
  • Subnormal serum erythropoietin alongside oxygen tension helps identify hemoglobin-related variants or mutations.
  • Analysis of conditions like renal artery stenosis and methemoglobinemia contribute to understanding underlying causes of erythrocytosis.
  • Phlebotomy and managing hyperviscosity symptoms may improve patient quality of life amidst varying genetic backgrounds.

Abstract

Abstract JAK2 unmutated/wild-type erythrocytosis is a prevalent condition encompassing a wide spectrum of hereditary and acquired entities. It is conventionally defined by the same hemoglobin/hematocrit thresholds as for polycythemia vera. Incidence has been reported to be between 0.13% and 4.1%. The most clinically relevant step in the workup of erythrocytosis is the exclusion of polycythemia vera through JAK2 mutation screening. Consideration of relative polycythemia, normal outliers, and the influence of erythropoietic drugs and comorbidities is also imperative. Distinguishing long-standing from newly acquired erythrocytosis further streamlines the diagnostic process. Hereditary erythrocytosis (HE) is lifelong and typically associated with a positive family history. Subnormal serum erythropoietin (EPO) suggests an EPO receptor mutation. Otherwise, oxygen tension at 50% hemoglobin saturation (p50) discerns between high oxygen-affinity hemoglobin variants, 3-bisphosphoglycerate deficiency, methemoglobinemia, and PIEZO1 mutations (low p50) and germline oxygen-sensing pathway/other rare mutations (normal p50). Acquired erythrocytosis results from hypoxia-driven factors (eg, cardiopulmonary, altitude, renal artery stenosis) and other mechanisms of EPO overproduction (eg, EPO-secreting tumors) or hypersensitivity, as well as EPO-independent mechanisms. Drugs (eg, sodium glucose co-transporter-2 inhibitors, testosterone) are also common causes. Idiopathic erythrocytosis is a diagnosis of exclusion, increasingly attributed to underlying genetic mutations/polymorphisms. There are currently no evidence-based treatment guidelines. Low-dose aspirin and/or phlebotomy (with frequency determined by symptom relief) might be considered on an individualized basis in the presence of hyperviscosity symptoms, cardiovascular comorbidities, and/or a history of thrombosis. Aggressive control of cardiovascular risk factors is recommended in all. A graphic abstract representation is provided in Figure 1.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Szuber et al. (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc1cahttps://doi.org/10.1182/hematology.2025000704
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Erythrocytosis: Diagnosis and investigation2024 · 6 citations
  2. 2Post-Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma: Molecular Mechanisms Underlying the Pathogenesis of Erythrocytosis2026
  3. 3Impaired iron balance and erythrocytosis: a complex relationship2026
  4. 4Genetic Markers of Erythrocytosis: Can the Presence of JAK2 Mutation Be Determined via Complete Blood Count Parameters and/or Serum Erythropoietin Level?2026
  5. 5Next-generation sequencing panel for hereditary erythrocytosis identifies genomic variants in over half of adults with otherwise unexplained erythrocytosis2025